kwic
further
further
right
off
ON
136
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for further out of >500 occurrences
298283 occurrences (No.79 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to further]
298283 occurrences (No.79 in the rank) during 5 years in the PubMed. [cache]
| 136) This finding may be important to consider when administering narrow-therapeutic-index medications metabolized by CYP2C9 and also compels further investigation to characterize novel genetic variation in understudied populations. |
| PMID:33632714 DOI:10.1124/dmd.120.000301 |
| 2021 Drug metabolism and disposition: the biological fate of chemicals |
| * In Vivo Functional Effects of CYP2C9 M1L, a Novel and Common Variant in the Yup'ik Alaska Native Population. |
| - Alaska Native people are under-represented in genetic research but have unique gene variation that may critically impact their response to pharmacotherapy. Full resequencing of CYP2C9 in a cross-section of this population identified CYP2C9 Met1Leu (M1L), a novel, relatively common single nucleotide polymorphism hypothesized to confer CYP2C9 poor metabolizer phenotype by disrupting the start codon. M1L is present at a minor allele frequency of 6.3% in Yup'ik Alaska Native people and thus can contribute to the risk of an adverse drug response from narrow-therapeutic-index CYP2C9 substrates such as (S)-warfarin. This study's objective was to characterize the catalytic efficiency of the Leu1 variant enzyme in vivo by evaluating the pharmacokinetic behavior of naproxen, a probe substrate for CYP2C9 activity, in genotyped Yup'ik participants. We first confirmed the selectivity of (S)-naproxen O-demethylation by CYP2C9 using activity-phenotyped human liver microsomes and selective cytochrome P450 inhibitors and then developed and validated a novel liquid chromatography mass spectrometry method for simultaneous quantification of (S)-naproxen, (S)-O-desmethylnaproxen, and naproxen acyl glucuronide in human urine. The average ratio of (S)-O-desmethylnaproxen to unchanged (S)-naproxen in urine was 18.0 ± 8.0 (n = 11) for the homozygous CYP2C9Met1 reference group and 10.3 ± 6.6 (n = 11) for the Leu1 variant carrier group (P = 0.011). The effect of M1L variation on CYP2C9 function and its potential to alter the pharmacokinetics of drugs metabolized by the enzyme has clinical implications and should be included in a variant screening panel when pharmacogenetic testing in the Alaska Native population is warranted. SIGNIFICANCE STATEMENT: The novel CYP2C9 Met1Leu variant in Alaska Native people was recently identified. This study validated (S)-naproxen as a CYP2C9 probe substrate to characterize the in vivo functional activity of the CYP2C9 Leu1 variant. The results of this pharmacogenetic-pharmacokinetic study suggest that the CYP2C9 Leu1 variant exhibits loss of enzyme activity. This finding may be important to consider when administering narrow-therapeutic-index medications metabolized by CYP2C9 and also compels further investigation to characterize novel genetic variation in understudied populations. |
[
right
kwic]
(1)83  research |
(16)4 validation |
(31)2 and |
(46)2 high-quality |
| (2)43 studies |
(17)3 confirmed |
(32)2 attention |
(47)2 inform |
| (3)22 investigation |
(18)3 demonstrate |
(33)2 characterization |
(48)2 insight |
| (4)9 analysis |
(19)3 demonstrated |
(34)2 clinical |
(49)2 reduce |
| (5)9 study |
(20)3 highlight |
(35)2 considerations |
(50)2 research, |
| (6)7 the |
(21)3 identify |
(36)2 develop |
(51)2 revealed |
| (7)7 work |
(22)3 in |
(37)2 developing |
(52)2 screening |
| (8)5 development |
(23)3 investigated |
(38)2 discussion |
(53)2 showed |
| (9)5 evidence |
(24)3 investigations |
(39)2 divided |
(54)2 structure-based |
| (10)4 evaluate |
(25)3 literature |
(40)2 enhanced |
(55)2 studied |
| (11)4 evaluation |
(26)3 our |
(41)2 evaluated |
(56)2 supported |
| (12)4 exploration |
(27)3 show |
(42)2 evaluations |
(57)2 tested |
| (13)4 explore |
(28)3 we |
(43)2 examined |
(58)2 this |
| (14)4 improve |
(29)2 aid |
(44)2 explored |
(59)2 understand |
| (15)4 investigate |
(30)2 analyses |
(45)2 extend |
(60)2 understanding |
add keyword
--- WordNet output for further ---